13F-HR filed by Sanofi
Sanofi filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-05 13:35:59 UTC, with 16 holding rows worth $629,867,590.
- Accession
- 0001193125-26-448717
- Filer
- CIK 1121404
- Filed
- 2026-11-05
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 16 entries on the cover page, a total value of $629,867,590 stated on the cover page (in dollars after the unit check, H1), rows summing to $629,867,590 with VALUE read as dollars as filed, 13F file number 028-25202. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| MEIRAGTX HOLDINGS PLC | G59665102 | COMMON STOCK | 12,197,737 | $134,175,107 | dollars as filed | |
| INHIBRX BIOSCIENCES INC | 45720N103 | COM | 1,157,926 | $115,885,234 | dollars as filed | |
| NOVAVAX INC | 670002401 | COM NEW | 6,880,481 | $74,378,000 | dollars as filed | |
| KORSANA BIOSCIENCES INC | 23255M303 | COMMON STOCK | 1,994,011 | $63,808,352 | dollars as filed | |
| Odyssey Therapeutics, Inc. | 67613T104 | COMMON STOCK | 1,990,200 | $44,222,244 | dollars as filed | |
| ANAPTYSBIO INC | 032724106 | COM | 821,917 | $41,309,548 | dollars as filed | |
| AGOMAB THERAPEUTICS NV | 00860C102 | SPONSORED ADS | 2,783,096 | $30,892,366 | dollars as filed | |
| FIRST TRACKS BIOTHERAPEUTICS | 337185102 | ORD SHS *A* | 821,917 | $29,128,738 | dollars as filed | |
| Electra Therapeutics, Inc. | 284825106 | Common Stock, $0.0001 par value per share | 2,461,948 | $27,696,915 | dollars as filed | |
| ATTOVIA THERAPEUTICS INC | 04987L102 | COM | 1,082,855 | $18,560,135 | dollars as filed | |
| Latigo Biotherapeutics, Inc. | 517954103 | Common Stock, par value $0.0001 per share | 672,778 | $11,235,393 | dollars as filed | |
| IMMUNEERING CORP | 45254E107 | CLASS A COM | 2,708,559 | $11,091,549 | dollars as filed | |
| MAPLIGHT THERAPEUTICS INC | 56565P103 | COMMON STOCK | 912,041 | $9,293,698 | dollars as filed | |
| SCRIBE THERAPEUTIC COM | 811033109 | COM | 500,000 | $9,202,500 | dollars as filed | |
| SAB BIOTHERAPEUTICS INC | 78397T202 | COMMON STOCK | 2,198,500 | $6,969,245 | dollars as filed | |
| Q32 BIO INC | 746964105 | Common Stock | 244,083 | $2,018,566 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001193125-26-448717 | this filing | 2026-11-05 |